Hormone replacement therapy combined with testosterone for the treatment of hypoactive sexual desire disorder in climacteric women

Terapia de reemplazo hormonal combinada con testosterona para el tratamiento del trastorno del deseo sexual hipoactivo en mujeres en climaterio

Published 2019-12-14


https://doi.org/10.30554/archmed.20.1.3388.2020
Open | Download
PDF (Spanish) FLIP EPUB (Spanish) HTML (Spanish) PDF (Marcado) (Spanish) FLIP EPUB (Marcado) (Spanish) XML (Spanish)
Issue
Vol. 20 No. 1 (2020)
Section
Research Articles
How to Cite
Espitia De La Hoz, F. J. (2019). Hormone replacement therapy combined with testosterone for the treatment of hypoactive sexual desire disorder in climacteric women. Archivos De Medicina (Manizales), 20(1), 71-85. https://doi.org/10.30554/archmed.20.1.3388.2020
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
DOI

https://doi.org/10.30554/archmed.20.1.3388.2020
Dimensions
PlumX

How to Cite

Espitia De La Hoz, F. J. (2019). Hormone replacement therapy combined with testosterone for the treatment of hypoactive sexual desire disorder in climacteric women. Archivos De Medicina (Manizales), 20(1), 71-85. https://doi.org/10.30554/archmed.20.1.3388.2020

Download Citation

Franklin Jose Espitia De La Hoz
Perfil Google Scholar
https://orcid.org/0000-0002-4581-9680 ORCID
Show authors biography

Franklin Jose Espitia De La Hoz,

Especialista en Ginecología y Obstetricia / Universidad Militar Nueva Granada.

Médico especialista en Sexualidad femenina.

Especialista en Uroginecología y cirugía reconstructiva del piso pélvico / UNal, FUCS, Unicamp (Brasil).

Especialista en Ginecología Cosmética y Rejuvenecimiento Vaginal con Láser / FUCS, Sociedade Brasileira de laser em medicina e cirugia (Brasil).

Presidente Asociación Quindiana de Obstetricia y Ginecología (AQOG).

 

Most read articles by the same author(s)

Objective: to evaluate the efficacy and safety of two hormone replacement therapies, combined with testosterone, in the treatment of hypoactive sexual desire disorder in women in climacteric. Materials and methods: clinical trial, randomized, controlled, not masked. Women over 40 years old and under 60 years old, with a uterus, with sexual activity in the last six weeks, suffering from vasomotor symptoms, whose reason for consultation consisted of low sexual desire were included. The Female Sexual Function Index questionnaire was used as an instrument. Two randomized groups were assigned: group "A" (51 received conjugated estrogens from equines and medroxyprogesterone plus testosterone) and group "B" (54 tibolone plus testosterone). The study was conducted between July 2015 and December 2016, in Armenia, Quindío, Colombia. Results: a population of 105 women was analyzed. The average age was 55,8 (SD ± 9,38) years. In the total population, at the beginning of the study, the median was 3 sexual encounters per month. In the end, the median was 5 sexual encounters per month, (group «A» 4 meetings and group «B» 7 meetings, p = 0,0036). At the end of the investigation, it was observed that the women of the «B» group showed significantly higher average scores in the IFSF (28,56 SD ± 4,63 points), compared with values ​​in the women of the «A» group (27,57 DS ± 4,32) (p <0,0001). Conclusions: testosterone-associated tibolone therapy is an effective treatment option in hypoactive sexual desire disorder in women in climacteric.

 

Article visits | PDF visits

Downloads

Download data is not yet available.
  1. Basson R. Women’s sexual function: revised and expanded definitions. CMAJ 2005; 172:1327-33. DOI: 10.1503/cmaj.1020174
  2. Lodise NM. Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health. Pharmacotherapy 2013; 33(4):411-21. DOI:10.1002/phar.1209
  3. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008; 112(5):970–8. DOI: 10.1097/AOG.0b013e3181898cdb
  4. Espitia-De La Hoz FJ. Evaluación de la prevalencia de disfunción sexual en mujeres médicos, del Eje Cafetero colombiano, en etapa de climaterio. Arch Med (Manizales) 2017; 17(1):70-7. DOI: https://doi.org/10.30554/archmed.17.1.1897.2017
  5. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of western European women. J Sex Med 2006; 3(2):212–22. DOI:10.1111/j.1743-6109.2006.00215.x
  6. Leiblum S, Koochaki P, Rodenberg C, Barton I, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women’s International Study of Health and Sexuality (WISHeS). Menopause 2006; 13(1):46–56.
  7. Espitia-De-La- Hoz FJ. Prevalence and characterisation of sexual dysfunctions in women, in 12 Colombian cities, 2009-2016. Rev Colomb Obstet Ginecol 2018; 69:9-21. DOI:10.18597/rcog.3035
  8. Raigosa-Londoño G, Echeverri-Ramírez MC. Prevalencia del desorden de deseo sexual hipoactivo en mujeres colombianas y factores asociados. Rev Colomb Obstet Ginecol 2012; 63(2):127-33.
  9. Echeverri MC, Arango A, Castro B, Raigosa G. Study of the Prevalence of Female Sexual Dysfunction in Sexually Active Women 18 to 40 years of age in Medellín, Colombia. J Sex Med 2010; 7:2363-9.
  10. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI). A multidimensional self-report instrument for the assessment of female sexual function. Journal of Sex & Marital Therapy 2000; 26:191-208. DOI: 10.1080/009262300278597
  11. Espitia de la Hoz FJ, Marega O, Orozco Gallego H. Manejo farmacológico de la disfunción sexual femenina en la postmenopausia, con tibolona y testosterona. Revista de Sexologia 2016; 5(2):9-18.
  12. Kingsberg SA, Woodard T. Female sexual dysfunction: Focus on low desire. Obstet Gynecol 2015; 125:477-86. DOI:10.1097/AOG.0000000000000620
  13. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med 2005; 2(3):154-65. DOI:10.1111/j.1743-6109.2005.00131.x
  14. Hickey M, Elliott J, Davison SL. Hormone replacement therapy. BMJ 2012; 344:763.
  15. Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric 2010; 13(2):147-56. DOI:10.1080/13697130903009195
  16. Somboonporn W, Davis S, Seif MW, Bell R: Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005; 19;(4):CD004509. DOI:10.1002/14651858.CD004509.pub2
  17. Tuiten A, Van Honk J, Koppeschaar H et al: Time course of effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry 2000; 57(2): 149–53; discussion 155–6. DOI:10.1001/archpsyc.57.2.149
  18. Aedo S, Cavada G, Blümel JE, Chedraui P, Fica J, Barriga P, et al. Women's Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks. Menopause 2015; 22(12):1317-22. DOI: 10.1097/GME.0000000000000472
  19. Blümel J, Binfa L, Cataldo P, Carrasco A, Izaguirre H, Sarrá S. Índice de la Función Sexual Femenina: un test para evaluar la sexualidad de la mujer. Rev Chil Obstet Ginecol 2004; 69:118-25. DOI: http://dx.doi.org/10.4067/S0717-75262004000200006
  20. Rexrode KM, Manson JE, Lee IM, Ridker PM, Sluss PM, Cook NR, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 2003; 108(14):1688-93. DOI: 10.1161/01.CIR.0000091114.36254.F3
  21. Huang KE, Baber R; Asia Pacific Tibolone Consensus Group. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric 2010; 13(4):317-27. DOI: 10.3109/13697131003681458
  22. Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A. A comparative study of the eff ects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 2010; 7:1284–90.
  23. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010; 13(2):121-31. DOI: 10.3109/13697131003675922
  24. Liu JH. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms. Am J Med 2005; 118 Suppl 12B:88-92. DOI: 10.1016/j.amjmed.2005.09.040
  25. Kenemans P, Speroff L; International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005; 51(1):21-8. DOI: 10.1016/j.maturitas.2005.02.011
  26. Espitia-De La Hoz, FJ, Orozco, Gallego, H, Echeverri, Ocampo, LM. Terapia hormonal y no hormonal en la vaginitis atrófica posmenopáusica: cura y satisfacción a mediano y a largo plazo de los síntomas. Rev Col de menopausia 2016; 22(1):8-17.
  27. Espitia-De La Hoz FJ. Prevalence of genitourinary syndrome of menopause and impact on sexuality of women in Quindío (Colombia), 2013-2016. Rev Colomb Obstet Ginecol 2018; 69(4):249-59. http://dx.doi.org/10.18597/rcog.3111
  28. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) Survey. J Sex Med 2013; 10(7):1790–1799. DOI: 10.1111/jsm.12190
  29. Kalogeraki A, Tamiolakis D, Relakis K, Karvelas K, Froudarakis G, Hassan E, et al. Cigarette smoking and vaginal atrophy in postmenopausal women. In Vivo 1996; 10:597–600.
  30. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 1983; 249:2195–8
  31. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005; 52(1):46–52. DOI: 10.1016/j.maturitas.2005.06.014
  32. Pan HA, Wang ST, Pai MC, Chen CH, Wu MH, Huang KE. Cognitive function variations in postmenopausal women treated with continuous combined HRT or tibolone. A comparison. J Reprod Med 2003; 48:375-80.
  33. Espitia-De La Hoz FJ, Orozco-Gallego H. Estriol vs estrógenos conjugados de origen equino en el tratamiento del síndrome genitourinario de la menopausia. Ginecol Obstet Mex 2018; 86:117-26. https://doi.org/10.24245/gom.v86i2.1881
  34. Espitia-De La Hoz FJ. Efficacy and tolerance of policresulen in the treatment of the genitourinary syndrome of menopause. Int J Fam Commun Med 2019; 3(3):132‒136. DOI: 10.15406/ijfcm.2019.03.00145
  35. Wenderlein JM. [The effect of estrogen therapy on sexuality. Observations on 122 postmenopausal women]. MMW Munch Med Wochenschr 1981; 10; 123(15):609-10.
  36. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90(9):5226-33. DOI: 10.1210/jc.2004-1747

Information

Google Scholar Profile

Author Guidelines